Meisoindigo is a derivative of indirubin (Item No.
14155) that has anticancer activity.
1 It inhibits the growth of NB4, HL-60, and U937 leukemia and primary acute myeloid leukemia (AML) cells when used at concentrations of 5 and 10 μM. It also halts the cell cycle at the G
0/G
1 phase and induces apoptosis in leukemia cell lines and primary AML cells, induces myeloid differentiation, and potentiates the effects of cytarabine (Item No.
16069) and idarubicin (Item No.
14176). Meisoindigo (10 μM) also induces apoptosis, decreases adherence, and decreases the expression of vascular cell adhesion molecule-1 (VCAM-1) in ECV304 human vein endothelial cells.
2 Meisoindigo (50-150 mg/kg per day) decreases spleen size in an HL-60 mouse xenograft model of AML in a dose-dependent manner.